Study of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma/Metastatic Liver Tumors

Phase 1

• Conditions: hepatocellular carcinoma, liver neoplasms; D006528, D008113

• Registration Number: JPRN-jRCT1030220731
• Lead Sponsor: Yamashita Hideomi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-03-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

a) Patients with pathologically or clinically (by dynamic contrast-enhanced CT or EOB-MRI of the liver) diagnosed primary or recurrent hepatocellular carcinoma or localized metastatic liver tumor who are not candidates for radical treatment (liver resection, RFA, liver transplantation) and will receive stereotactic body radiation therapy.
b) Patients whose pre-enrollment treatment plan meets the dose constraints.
c) Patients with Child-pugh classification grade A or B.
d) Performance status (PS) of 0-2.
e) Over 18 years old.
f) Patients who have given their written consent to participate in the study.

Exclusion Criteria

a) Patients who do not consent to participate in the study.
b) With lymph node metastasis or distant metastasis in other organs.
c) With a history of prior radiotherapy to liver.
d) With WBC <2,000/mm3, HB <8g/dl, or Plt <50.000/mm3.
e) Patients participating in other clinical trials that may affect the conduct or outcome of this study.
f) Other patients who are deemed inappropriate to participate in this study by the investigator or co-investigaters.

Study & Design

• Study Type: Interventional
• Study Design: Not specified